Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis
- PMID: 16634716
- DOI: 10.1517/14656566.7.7.941
Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis
Abstract
Allergic rhinitis symptoms, in particular nasal congestion, can have a significant impact on patient quality of life, resulting in reduced productivity and daytime sleepiness. Newer-generation antihistamines are commonly used to treat allergic rhinitis; however, in patients with severe congestion, a combination of a newer-generation antihistamine and a decongestant is particularly beneficial. A new once-daily fexofenadine/pseudoephedrine combination has been developed and recently approved in the US. The combination provides an effective, well-tolerated antihistamine and a reliable, sustained-release pseudoephedrine system. In addition, small tablet size and once-daily dosing may provide patients with increased convenience and improve adherence. In summary, the combination of immediate-release fexofenadine/sustained-release pseudoephedrine offers an important additional option for the treatment of allergic rhinitis.
Similar articles
-
The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.J Allergy Clin Immunol. 1999 Jul;104(1):100-6. doi: 10.1016/s0091-6749(99)70120-x. J Allergy Clin Immunol. 1999. PMID: 10400846 Clinical Trial.
-
Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis.Ann Allergy Asthma Immunol. 2004 Jan;92(1):73-9. doi: 10.1016/S1081-1206(10)61713-9. Ann Allergy Asthma Immunol. 2004. PMID: 14756468 Clinical Trial.
-
Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.Drugs. 2000 Feb;59(2):301-21. doi: 10.2165/00003495-200059020-00020. Drugs. 2000. PMID: 10730552
-
A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. Clin Ther. 2009. PMID: 19539095 Review.
-
Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):683-94. doi: 10.1517/17425250902980187. Expert Opin Drug Metab Toxicol. 2009. PMID: 19473112 Review.
Cited by
-
Application of green first derivative synchronous spectrofluorometric method for quantitative analysis of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pharmaceutical preparation and spiked human plasma.BMC Chem. 2022 Aug 19;16(1):62. doi: 10.1186/s13065-022-00855-5. BMC Chem. 2022. PMID: 35986381 Free PMC article.
-
Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.AAPS J. 2017 Jul;19(4):1045-1053. doi: 10.1208/s12248-017-0075-7. Epub 2017 Mar 29. AAPS J. 2017. PMID: 28357656
-
Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers.Clin Pharmacol Ther. 2022 Sep;112(3):627-634. doi: 10.1002/cpt.2682. Epub 2022 Jun 29. Clin Pharmacol Ther. 2022. PMID: 35678032 Free PMC article. Clinical Trial.
-
Position statement of the Brazilian Academy of Rhinology on the use of antihistamines, antileukotrienes, and oral corticosteroids in the treatment of inflammatory sinonasal diseases.Braz J Otorhinolaryngol. 2017 Mar-Apr;83(2):215-227. doi: 10.1016/j.bjorl.2017.01.002. Epub 2017 Jan 21. Braz J Otorhinolaryngol. 2017. PMID: 28216249 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical